Ark Therapeutics Group PLC unveiled plans to tap investors for 27.1 mln stg to fund the development of its experimental drug programmes, prepare for the launch of its second product, and scale up manufacturing facilities in Finland.
Ark Therapeutics Group PLC unveiled plans to tap investors for 27.1 mln stg to fund the development of its experimental drug programmes, prepare for the launch of its second product, and scale up manufacturing facilities in Finland.
